ESMO 2017: Study in Early Stage Breast Cancer Shows That Even Small Tumours Can Be Aggressive

Google+ Pinterest LinkedIn Tumblr +

Even small tumours can be aggressive, according to a study in patients with early stage breast cancer that will be presented at the ESMO 2017 Congress in Madrid. (1)

Researchers found that nearly one in four small tumours were aggressive and patients benefited from chemotherapy. Aggressive tumours could be identified by a 70-gene signature.

“Our results challenge the assumption that all small tumours are less serious and do not need adjuvant chemotherapy,” said lead author Dr Konstantinos Tryfonidis, a researcher at the European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

The MINDACT study is managed and sponsored by the EORTC in collaboration with the Breast International Group (BIG) and included 6,693 women with early stage breast cancer (lymph node negative or 1-3 lymph node positive). (2) As previously reported, MINDACT showed that around 46% of patients who were at high clinical risk for recurrence, defined using Adjuvant! might not require chemotherapy. (3) These women had a low genomic risk for recurrence according to MammaPrint, a genomic signature that assists in predicting clinical outcomes in women with early stage breast cancer. (3,4)

The sub analysis presented at ESMO 2017 included the 826 patients in MINDACT with a primary tumour size of less than 1 cm (pT1abpN0). Clinical and genomic risks were assessed and 196 patients (24%) were found to be at clinical low risk and genomic high risk. These patients were randomised to receive, or not receive, chemotherapy.

The researchers found that at five years, very few patients who received chemotherapy experienced disease relapses, showing high rates of distant metastases-free survival, disease-free survival and overall survival, which confirms that they derived benefit from chemotherapy.

“We found that nearly one in four patients with small tumours are at risk of distant metastases and do benefit from chemotherapy,” said Dr Fatima Cardoso, senior author of the study, Co-Principal Investigator of MINDACT and Director of the Breast Unit of the Champalimaud Clinical Centre, Lisbon, Portugal. “This was striking because based on clinical criteria alone you would say that these tumours are not aggressive and therefore patients do not need chemotherapy. But 24% of small tumours had an aggressive biology, which shows that not all small tumours are the same.”

Commenting on the results for ESMO, Dr Evandro de Azambuja, Head of the Medical Support Team, Academic Promoting Team, Jules Bordet Institute, Brussels, Belgium, said: “This study shows that it’s not only tumour size that is important for breast cancer patients but also tumour biology. All tumours in the study were small – less than 1 cm – and the lymph nodes were free of cancer (node negative), which in principle should be a signal of good prognosis. But nearly one in four patients – those identified as genomic high risk – derived benefit from chemotherapy.”

“Small node negative tumours can be very aggressive, even if they are classified as clinical low risk,” said de Azambuja. “Tumour biology needs to be taken into account when deciding adjuvant treatments in this patient population. One cannot forget the patient’s age, performance status, comorbidities and preferences during the discussion.”


SourceESMO 2017 Congress

References:

  1. Abstract 150O_PR ‘Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy‘ presented by Dr Konstantinos Tryfonidis during Proffered Paper Session ‘Breast cancer, early stage’ on Friday, 8 September 2017, 14:00 to 15:30 (CEST) in the Pamplona Auditorium.
  2. The MINDACT study is managed and sponsored by the EORTC in collaboration with the Breast International Group (BIG), Agendia, and many other academic and commercial partners, as well as patient advocates.
  3. Cardoso F, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med . 2016;375(8):717–729. doi: 10.1056/NEJMoa1602253.
  4. van de Vijver MJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.
Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply